BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37431168)

  • 1. Increased risk for incisional hernia following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Ben-Yaacov A; Laks S; Zoabi G; Kirshenboim Z; Goldenshlger A; Hazzan D; Westrich G; Owda Y; Segev L; Nissan A; Goldenshluger M
    ANZ J Surg; 2023 Sep; 93(9):2192-2196. PubMed ID: 37431168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of incisional hernia in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: an observational clinical study from a tertiary oncology referral care center in India.
    Ray M; Kumar A; Maranna H
    World J Surg Oncol; 2024 May; 22(1):132. PubMed ID: 38760663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incisional hernias post cytoreductive surgery/peritonectomy and hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis.
    Mac Curtain BM; Qian W; Temperley HC; Simpkin AJ; Ng ZQ
    Hernia; 2023 Oct; 27(5):1067-1083. PubMed ID: 37653188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and predictors of incisional hernia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Tuttle TM; Huang JL; Kizy S; Altman AM; Nalluri H; Marmor S; Gaertner WB; Jensen EH; Hui JYC
    Int J Hyperthermia; 2019; 36(1):812-816. PubMed ID: 31451032
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk factors and management of incisional hernia after cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal surface malignancies.
    Cascales Campos PA; González-Gil A; Gómez-Ruiz AJ; Gil-Gómez E; Alconchel-Gago F; Navarro-Barrios A; Martínez-García J; Alonso-Romero JL; Nieto A; Barceló-Valcarcel F; Gil-Martínez J
    Hernia; 2020 Apr; 24(2):257-263. PubMed ID: 31069579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abdominal Wall Morbidity Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Struller F; Koenigsrainer I; Horvath P; Koenigsrainer A; Beckert S
    Scand J Surg; 2017 Dec; 106(4):294-298. PubMed ID: 28737098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incisional hernia and its impact on health-related quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a national prospective cohort study.
    Ravn S; Thaysen HV; Harsløf S; Sørensen MM; Iversen LH
    World J Surg Oncol; 2018 Apr; 16(1):85. PubMed ID: 29695230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 10. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
    [No Abstract]   [Full Text] [Related]  

  • 11. Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
    Hanna DN; Ghani MO; Hermina A; Mina A; Bailey CE; Idrees K; Magge D
    Am Surg; 2022 Apr; 88(4):698-703. PubMed ID: 34732056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palliative Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Is It Safe and Effective?
    Strong EA; Livingston A; Gracz M; Peltier W; Tsai S; Christians K; Gamblin TC; Kersting K; Clarke CN
    J Surg Res; 2022 Oct; 278():31-38. PubMed ID: 35588572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.
    Chang SC; Fingerhut A; Chen WT
    Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Elderly is Safe and Effective.
    Laks S; Bilik A; Schtrechman G; Adileh M; Mor E; Boursi B; Halpern N; Margalit O; Shacham-Shmueli E; Nissan A; Ben-Yaacov A
    J Surg Res; 2022 Nov; 279():739-747. PubMed ID: 35940050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases.
    Steinhoff H; Acs M; Blaj S; Dank M; Herold M; Herold Z; Herzberg J; Sanchez-Velazquez P; Strate T; Szasz AM; Piso P
    World J Gastroenterol; 2023 May; 29(18):2850-2863. PubMed ID: 37274066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced peritoneal surface tumors during the COVID-19 pandemic: A single-institution experience.
    Radomski SN; Florissi I; Khan H; Siddiqi A; Paneitz DC; Johnston FM; Greer JB
    J Surg Oncol; 2022 Dec; 126(8):1375-1382. PubMed ID: 36081374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis.
    Hajjar R; Mercier F; Passot G; Pasquer A; Gelli M; Levine EA; Villeneuve L; Poncet G; Walter T; Glehen O
    Eur J Surg Oncol; 2022 Jul; 48(7):1626-1630. PubMed ID: 35418324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.